Partial target organ resistance to thyroid hormone.
PDF (1.1M)
Journal: 1973/May - Journal of Clinical Investigation
ISSN: 0021-9738
Abstract:
An 8-year old boy with a small goiter, normal basal metabolic rate (BMR), and elevated serum thyroid hormone levels (thyroxine [T(4)] 19.5 mug per 100 ml, free T(4) 4 ng per 100 ml, triiodothyronine [T(3)] 505 ng per 100 ml) was studied. He had measurable serum thyroid-stimulating hormone (TSH) levels (average 5.5 muU per ml), and the thyroxine-binding proteins, hearing, and epiphyseal structures were normal. There was no parental consanguinity nor were there thyroid abnormalities either in the parents or six siblings.Methimazole, 50 mg daily, depressed thyroxine synthesis (T(4) 10.5, free T(4) 2.5) and caused a rise in TSH to 11 muU per ml. After discontinuation of treatment, TSH declined to 4.2 muU per ml and chemical hyperthyroidism returned (T(4) 21.0 mug per 100 ml, free T(4) 4.2, and total T(3) 475 ng per 100 ml, radioactive iodine [RAI] uptake 68%), but studies of BMR and insensible water loss showed the patient to be clinically euthyroid. Thyrotropin-releasing hormone (TRH), 200 mug i.v., caused a brisk rise in TSH to 28 muU per ml, with T(4) rising to 28 mug per 100 ml, free T(4) to 5.6, and T(3) to 730 ng per 100 ml, thus indicating that the pituitary-thyroid system was intact and that the patient's TSH was biologically active. The unusual sensitivity of the pituitary cells to TRH in spite of the markedly elevated serum thyroid hormone levels also suggested that the pituitary was insensitive to suppression by T(3) or T(4). Serum dilution studies gave immunochemical evidence that this patient's TSH was normal. Neither propranolol, 60 mg, chlorpromazine, 30 mg, nor prednisone, 15 mg daily, influenced thyroid indices. Steroid treatment, however, suppressed the pituitary response to TRH, T(3) in doses increased over a period of 12 days to as much as 150 mug daily caused a rise in serum T(3) to above 800 ng per 100 ml, a decline of T(4) to euthyroid levels (T(4) 9.5 mug per 100 ml, free T(4) 1.6 ng per 100 ml), suppression of the RAI uptake from 68% to 35%, and marked blunting of the responses to TRH, but the BMR and insensible water loss remained normal. The data suggest that the patient's disorder is due to partial resistance to thyroid hormone.
Open in
PUBMED | DOI | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(11)
References
(19)
Diseases
(1)
Drugs
(7)
Chemicals
(4)
Organisms
(1)
Processes
(1)
Similar articles
Articles by the same authors
Discussion board
J Clin Invest 52(4): 776-782
PMID: 4632689

Partial Target Organ Resistance to Thyroid Hormone

Abstract

An 8-year old boy with a small goiter, normal basal metabolic rate (BMR), and elevated serum thyroid hormone levels (thyroxine [T4] 19.5 μg per 100 ml, free T4 4 ng per 100 ml, triiodothyronine [T3] 505 ng per 100 ml) was studied. He had measurable serum thyroid-stimulating hormone (TSH) levels (average 5.5 μU per ml), and the thyroxine-binding proteins, hearing, and epiphyseal structures were normal. There was no parental consanguinity nor were there thyroid abnormalities either in the parents or six siblings.

Methimazole, 50 mg daily, depressed thyroxine synthesis (T4 10.5, free T4 2.5) and caused a rise in TSH to 11 μU per ml. After discontinuation of treatment, TSH declined to 4.2 μU per ml and chemical hyperthyroidism returned (T4 21.0 μg per 100 ml, free T4 4.2, and total T3 475 ng per 100 ml, radioactive iodine [RAI] uptake 68%), but studies of BMR and insensible water loss showed the patient to be clinically euthyroid. Thyrotropin-releasing hormone (TRH), 200 μg i.v., caused a brisk rise in TSH to 28 μU per ml, with T4 rising to 28 μg per 100 ml, free T4 to 5.6, and T3 to 730 ng per 100 ml, thus indicating that the pituitary-thyroid system was intact and that the patient's TSH was biologically active. The unusual sensitivity of the pituitary cells to TRH in spite of the markedly elevated serum thyroid hormone levels also suggested that the pituitary was insensitive to suppression by T3 or T4. Serum dilution studies gave immunochemical evidence that this patient's TSH was normal. Neither propranolol, 60 mg, chlorpromazine, 30 mg, nor prednisone, 15 mg daily, influenced thyroid indices. Steroid treatment, however, suppressed the pituitary response to TRH, T3 in doses increased over a period of 12 days to as much as 150 μg daily caused a rise in serum T3 to above 800 ng per 100 ml, a decline of T4 to euthyroid levels (T4 9.5 μg per 100 ml, free T4 1.6 ng per 100 ml), suppression of the RAI uptake from 68% to 35%, and marked blunting of the responses to TRH, but the BMR and insensible water loss remained normal. The data suggest that the patient's disorder is due to partial resistance to thyroid hormone.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
icon of scanned page 776
776
icon of scanned page 777
777
icon of scanned page 778
778
icon of scanned page 779
779
icon of scanned page 780
780
icon of scanned page 781
781
icon of scanned page 782
782

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Refetoff S, DeWind LT, DeGroot LJ. Familial syndrome combining deaf-mutism, stuppled epiphyses, goiter and abnormally high PBI: possible target organ refractoriness to thyroid hormone. J Clin Endocrinol Metab. 1967 Feb;27(2):279–294. [PubMed] [Google Scholar]
  • Refetoff S, DeGroot LJ, Benard B, DeWind LT. Studies of a sibship with apparent hereditary resistance to the intracellular action of thyroid hormone. Metabolism. 1972 Aug;21(8):723–756. [PubMed] [Google Scholar]
  • Odell WD, Wilber JF, Utiger RD. Studies of thyrotropin physiology by means of radioimmunoassay. Recent Prog Horm Res. 1967;23:47–85. [PubMed] [Google Scholar]
  • HUNTER WM, GREENWOOD FC. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature. 1962 May 5;194:495–496. [PubMed] [Google Scholar]
  • Cassidy CE, Benotti J, Peno S. Clinical evaluation of the determination of thyroxine iodine. J Clin Endocrinol Metab. 1968 Mar;28(3):420–421. [PubMed] [Google Scholar]
  • Sterling K, Brenner MA. Free thyroxine in human serum: simplified measurement with the aid of magnesium precipitation. J Clin Invest. 1966 Jan;45(1):153–163.[PMC free article] [PubMed] [Google Scholar]
  • Sterling K, Bellabarba D, Newman ES, Brenner MA. Determination of triiodothyronine concentration in human serum. J Clin Invest. 1969 Jun;48(6):1150–1158.[PMC free article] [PubMed] [Google Scholar]
  • MCKENZIE JM. Studies on the thyroid activator of hyperthyroidism. J Clin Endocrinol Metab. 1961 Jun;21:635–647. [PubMed] [Google Scholar]
  • ELZINGA KE, CARR EA, Jr, BEIERWALTES WH. Adaptation of the standard Durrum-type cell for reverse-flow paper electrophoresis. Am J Clin Pathol. 1961 Aug;36:125–131. [PubMed] [Google Scholar]
  • Mitsuma T, Colucci J, Shenkman L, Hollander CS. Rapid simultaneous radioimmunoassay for triiodothyronine and thyroxine in unextracted serum. Biochem Biophys Res Commun. 1972 Mar 24;46(6):2107–2113. [PubMed] [Google Scholar]
  • Patel YC, Burger HG, Hudson B. Radioimmunoassay of serum thyrotropin: sensitivity and specificity. J Clin Endocrinol Metab. 1971 Nov;33(5):768–774. [PubMed] [Google Scholar]
  • Fleischer N, Burgus R, Vale W, Dunn T, Guillemin R. Preliminary observations on the effect of synthetic thyrotropin releasing factor on plasma thyrotropin levels in man. J Clin Endocrinol Metab. 1970 Jul;31(1):109–112. [PubMed] [Google Scholar]
  • Hershman JM, Pittman JA., Jr Utility of the radioimmunoassay of serum thyrotrophin in man. Ann Intern Med. 1971 Apr;74(4):481–490. [PubMed] [Google Scholar]
  • Wolff J, Jones AB. Inhibition of hormone-sensitive adenyl cyclase by phenothiazines. Proc Natl Acad Sci U S A. 1970 Feb;65(2):454–459.[PMC free article] [PubMed] [Google Scholar]
  • Emerson CH, Utiger RD. Hyperthyroidism and excessive thyrotropin secretion. N Engl J Med. 1972 Aug 17;287(7):328–333. [PubMed] [Google Scholar]
  • Galton VA, Inggar SH, Jimenez-Fonseca J, Hershman JM. Alterations in thyroid hormone economy in patients with hydatidiform mole. J Clin Invest. 1971 Jun;50(6):1345–1354.[PMC free article] [PubMed] [Google Scholar]
  • Nicoloff JT, Fisher DA, Appleman MD., Jr The role of glucocorticoids in the regulation of thyroid function in man. J Clin Invest. 1970 Oct;49(10):1922–1929.[PMC free article] [PubMed] [Google Scholar]
  • Wilber JF, Utiger RD. The effect of glucocorticoids on thyrotropin secretion. J Clin Invest. 1969 Nov;48(11):2096–2103.[PMC free article] [PubMed] [Google Scholar]
  • Sterling K, Refetoff S, Selenkow HA. T3 thyrotoxicosis. Thyrotoxicosis due to elevated serum triiodothyronine levels. JAMA. 1970 Jul 27;213(4):571–575. [PubMed] [Google Scholar]
Children's and Medical Services, Massachusetts General Hospital, Boston, Massachusetts 02114
Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02114
Department of Medicine, Harvard Medical School, Boston, Massachusetts 02114
Shriners Burns Institute, Boston, Massachusetts 02114
Copyright notice
Abstract
An 8-year old boy with a small goiter, normal basal metabolic rate (BMR), and elevated serum thyroid hormone levels (thyroxine [T4] 19.5 μg per 100 ml, free T4 4 ng per 100 ml, triiodothyronine [T3] 505 ng per 100 ml) was studied. He had measurable serum thyroid-stimulating hormone (TSH) levels (average 5.5 μU per ml), and the thyroxine-binding proteins, hearing, and epiphyseal structures were normal. There was no parental consanguinity nor were there thyroid abnormalities either in the parents or six siblings.Methimazole, 50 mg daily, depressed thyroxine synthesis (T4 10.5, free T4 2.5) and caused a rise in TSH to 11 μU per ml. After discontinuation of treatment, TSH declined to 4.2 μU per ml and chemical hyperthyroidism returned (T4 21.0 μg per 100 ml, free T4 4.2, and total T3 475 ng per 100 ml, radioactive iodine [RAI] uptake 68%), but studies of BMR and insensible water loss showed the patient to be clinically euthyroid. Thyrotropin-releasing hormone (TRH), 200 μg i.v., caused a brisk rise in TSH to 28 μU per ml, with T4 rising to 28 μg per 100 ml, free T4 to 5.6, and T3 to 730 ng per 100 ml, thus indicating that the pituitary-thyroid system was intact and that the patient's TSH was biologically active. The unusual sensitivity of the pituitary cells to TRH in spite of the markedly elevated serum thyroid hormone levels also suggested that the pituitary was insensitive to suppression by T3 or T4. Serum dilution studies gave immunochemical evidence that this patient's TSH was normal. Neither propranolol, 60 mg, chlorpromazine, 30 mg, nor prednisone, 15 mg daily, influenced thyroid indices. Steroid treatment, however, suppressed the pituitary response to TRH, T3 in doses increased over a period of 12 days to as much as 150 μg daily caused a rise in serum T3 to above 800 ng per 100 ml, a decline of T4 to euthyroid levels (T4 9.5 μg per 100 ml, free T4 1.6 ng per 100 ml), suppression of the RAI uptake from 68% to 35%, and marked blunting of the responses to TRH, but the BMR and insensible water loss remained normal. The data suggest that the patient's disorder is due to partial resistance to thyroid hormone.
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.